MODERN VASCULAR OF SOUTHAVEN, LLC, HOUSTON VASCULAR SPECIALISTS CORP., FORT WORTH VASCULAR SPECIALISTS GROUP, MODERN VASCULAR OF DENVER, LLC, and SAN ANTONIO VASCULAR SPECIALISTS CORP. v. QLARANT INTEGRITY SOLUTIONS, LLC

District Court, N.D. Texas·Decided August 11, 2026·No. 3:23-cv-01171·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

MODERN VASCULAR OF § SOUTHAVEN, LLC, HOUSTON § VASCULAR SPECIALISTS CORP., § FORT WORTH VASCULAR § SPECIALISTS GROUP, MODERN § VASCULAR OF DENVER, LLC, and § SAN ANTONIO VASCULAR § SPECIALISTS CORP., § § Plaintiffs, § § v. § Civil Action No. 3:23-CV-1171-K § QLARANT INTEGRITY SOLUTIONS, § LLC, § § Defendant. § MEMORANDUM OPINION AND ORDER Before the Court are Defendant Qlarant Integrity Solutions, LLC’s Motion to Dismiss pursuant to Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6) (Doc. No. 21) (the “Motion”), Plaintiffs’ Response (Doc. No. 25), and Defendant’s Reply (Doc. No. 28). The Court has carefully considered the Motion, Response, Reply, applicable law, and relevant portions of the record. For the following reasons, the Court concludes that it lacks subject-matter jurisdiction because Plaintiffs have not channeled their claims through the United States Department of Health and Human Services. Therefore, the Motion is GRANTED under Rule 12(b)(1). I. Factual and Procedural Background Plaintiffs Modern Vascular of Southaven, LLC; Houston Vascular Specialists

Corp.; Fort Worth Vascular Specialists Group; Modern Vascular of Denver, LLC; and San Antonio Vascular Specialists Corp. (collectively, “Plaintiffs”) own clinics that treat patients with peripheral arterial disease, including Medicare beneficiaries. Pls.’ Am. Compl. (Doc. No. 12) ¶¶ 10, 18 (all record citations herein are to the document

assigned page or paragraph numbers). Medicare is a national health insurance program administered by the Centers for Medicare & Medicaid Services (“CMS”), which is an agency within the United States Department of Health and Human Services (“HHS”). Doc. No. 21 at 1 n.1, 3. As Medicare providers, Plaintiffs submit claims for payment to Medicare Administrative Contractors (“MACs”). Doc. No. 12 ¶ 22. The claims

submitted to MACs are subject to review by Unified Program Integrity Contractors (“UPICs”), Doc. No. 21 at 1 n.1, who review the claims for suspected fraud, waste, abuse, and improper payment, Doc. No. 12 ¶¶ 21–22. Defendant Qlarant Integrity Solutions, LLC (“Defendant”) is a UPIC. Doc. No.

12 ¶¶ 15, 17. As a UPIC, Defendant is empowered to suspend payments, in whole or in part, when it determines there is a credible allegation of fraud against a provider. Doc. No. 21 at 3 (citing 42 C.F.R. § 405.372(a)(4)). Defendant operates in the “UPIC Southwestern” jurisdiction, meaning Defendant is responsible for reviewing Plaintiffs’ claims submitted to MACs. See Pls.’ Resp. (Doc. No. 25) at 2. On February 14, 2023, Defendant issued Notices of Payment Suspension (the “Suspension Notices”) to each Plaintiff pursuant to 42 C.F.R. § 405.371(a)(2). Doc.

No. 12-1 at 1, 3, 5, 7, 9. According to Defendant, CMS determined there were “credible allegations of fraud” related to Plaintiffs’ services billed to Medicare and suspended all Medicare payments to Plaintiffs. Id. Pursuant to 42 C.F.R. § 405.372(b)(2), the Suspension Notices informed Plaintiffs of their right to submit a rebuttal statement within 15 days, indicating why the provider believes the suspension should be removed.

Doc. No. 12 ¶ 22; Doc. No. 12-1 at 1–10. The Suspension Notices also stated that, if Plaintiffs chose to submit a rebuttal statement, Defendant would “review that statement (and any supporting documentation) along with other materials associated with the case.” Doc. No. 12 ¶ 22; Doc. No. 12-1 at 1–10. Then, based on a review of

the information Plaintiffs submitted and all other relevant information known to Defendant, Defendant would “determine whether the suspension should be removed, or should remain in effect within 15 days of receipt of the complete rebuttal package, consistent with 42 C.F.R. § 405.375.” Doc. No. 12 ¶ 22; Doc. No. 12-1 at 1–10.

Within their 15-day deadline, Plaintiffs submitted a Consolidated Rebuttal Statement to Defendant on February 27, 2023. Doc. No. 12 ¶ 25. Plaintiffs allege the Consolidated Rebuttal Statement was delivered to Defendant on February 28, 2023. Id. ¶¶ 26–29. However, Plaintiffs did not receive Defendant’s response until April 7, 2023, id. ¶ 28, which allegedly means Defendant failed to timely respond pursuant to

the 15-day deadline mentioned in Defendant’s Suspension Notices and 42 C.F.R. § 405.375, id. ¶¶ 26–29. Based on this failure, Plaintiffs claim they were (1) deprived of a variety of business opportunities, (2) forced to curtail most of their clinic

operations, and (3) forced to deprive patients of access to procedures. Id. ¶¶ 32–33, 35–36. Plaintiffs filed suit against Defendant in state court. See generally Pls.’ Orig. Pet. (Doc. No. 1-1). Plaintiffs claim Defendant’s alleged failure to timely respond, and the resulting harm, amount to (1) negligence, and (2) negligence per se in violation of 42

C.F.R. § 405.375 (collectively, the “Claims”). Doc. No. 12 at 8–9. Defendant removed the case to federal court based on federal officer removal jurisdiction and federal question jurisdiction with supplemental jurisdiction over state law claims. Notice of Removal (Doc. No. 1) at 3, 12 (citing 28 U.S.C. §§ 1367(a), 1442, and referencing

federal question jurisdiction); Def.’s Resp. to Ct. Order (Doc. No. 7) at 2 (clarifying that Defendant is not asserting diversity jurisdiction as basis for removal). Following removal, Plaintiffs timely filed an Amended Complaint. See generally Doc. No. 12. Defendant then moved to dismiss pursuant to Federal Rules of Civil Procedure

12(b)(1) and 12(b)(6). See generally Doc. No. 21. Plaintiffs responded to the Motion, see generally Doc. No. 25, and Defendant replied, see generally (Doc. No. 28. II. Legal Standard “Federal courts are courts of limited jurisdiction, and absent jurisdiction conferred by statute, lack the power to adjudicate claims.” La. Real Est. Appraisers Bd.

v. Fed. Trade Comm'n, 917 F.3d 389, 391 (5th Cir. 2019) (quoting Texas v. Travis Cnty., 910 F.3d 809, 811 (5th Cir. 2018)). Courts “must presume that a suit lies outside this limited jurisdiction, and the burden of establishing federal jurisdiction rests on the

party seeking the federal forum.” Howery v. Allstate Ins. Co., 243 F.3d 912, 916 (5th Cir. 2001) (citing Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375, 377 (1994)). Under Rule 12(b)(1), a party may challenge the subject-matter jurisdiction of the district court to hear a case. FED. R. CIV. P. 12(b)(1). The district court may dismiss for lack of subject-matter jurisdiction based on the complaint alone. Ramming v. United

Free access — add to your briefcase to read the full text and ask questions with AI

MODERN VASCULAR OF SOUTHAVEN, LLC, HOUSTON VASCULAR SPECIALISTS CORP., FORT WORTH VASCULAR SPECIALISTS GROUP, MODERN VASCULAR OF DENVER, LLC, and SAN ANTONIO VASCULAR SPECIALISTS CORP. v. QLARANT INTEGRITY SOLUTIONS, LLC, (N.D. Tex. 2026).

MODERN VASCULAR OF SOUTHAVEN, LLC, HOUSTON VASCULAR SPECIALISTS CORP., FORT WORTH VASCULAR SPECIALISTS GROUP, MODERN VASCULAR OF DENVER, LLC, and SAN ANTONIO VASCULAR SPECIALISTS CORP. v. QLARANT INTEGRITY SOLUTIONS, LLC (MODERN VASCULAR OF SOUTHAVEN, LLC, HOUSTON VASCULAR SPECIALISTS CORP., FORT WORTH VASCULAR SPECIALISTS GROUP, MODERN VASCULAR OF DENVER, LLC, and SAN ANTONIO VASCULAR SPECIALISTS CORP. v. QLARANT INTEGRITY SOLUTIONS, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Howery v. Allstate Ins Company
243 F.3d 912 (Fifth Circuit, 2001)
Weinberger v. Salfi
422 U.S. 749 (Supreme Court, 1975)
Heckler v. Ringer
466 U.S. 602 (Supreme Court, 1984)
Mesa v. California
489 U.S. 121 (Supreme Court, 1989)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
RANDALL D. WOLCOTT, MD, PA v. Sebelius
635 F.3d 757 (Fifth Circuit, 2011)
Physician Hospitals of America v. Kathleen
691 F.3d 649 (Fifth Circuit, 2012)
Alabama-Coushatta Tribe of TX v. USA
757 F.3d 484 (Fifth Circuit, 2014)
La. Real Estate Appraisers Bd. v. Fed. Trade Comm'n
917 F.3d 389 (Fifth Circuit, 2019)
Family Rehab., Inc. v. Azar
886 F.3d 496 (Fifth Circuit, 2018)
Tex. v. Travis Cnty.
910 F.3d 809 (Fifth Circuit, 2018)
Natl Infusion Center v. Becerra
116 F.4th 488 (Fifth Circuit, 2024)